Testosterone/androstenedione ratio in the evaluation of women with ovarian androgen excess.
A plasma testosterone/androstenedione (T/A) ratio was calculated in 15 women with possible ovarian neoplasms and androgen excess and whose mean plasma concentration of testosterone approached or was greater than a twofold elevation. The T/A ratio approached unity in eight of nine patients with polycystic ovarian disease, whereas all patients with hyperthecosis and two of three patients with androgen-secreting tumors had a testosterone/androstenedione ratio above 1.5. In 13 of 16 patients with androgen-secreting tumors of the ovary reported in the literature, the testosterone/androstenedione ratio was above 1.5. An elevated testosterone/androstenedione ratio should raise the suspicion of either an ovarian androgen-secreting tumor or hyperthecosis.
D000293:Adolescent; D000328:Adult; D000735:Androstenedione / Q000097:blood*; D003687:Dehydroepiandrosterone / Q000031:analogs & derivatives / Q000097:blood; D019314:Dehydroepiandrosterone Sulfate; D005260:Female; D006801:Humans; D006965:Hyperplasia; D007984:Leydig Cell Tumor / Q000097:blood; D008875:Middle Aged; D010048:Ovarian Cysts / Q000097:blood*; D010051:Ovarian Neoplasms / Q000097:blood*; D010053:Ovary / Q000473:pathology; D018310:Sertoli-Leydig Cell Tumor / Q000097:blood; D013739:Testosterone / Q000097:blood*
D013739:Testosterone; D000735:Androstenedione; D003687:Dehydroepiandrosterone; D019314:Dehydroepiandrosterone Sulfate